MX2022000376A - Aminopirimidinas como inhibidores de alk. - Google Patents

Aminopirimidinas como inhibidores de alk.

Info

Publication number
MX2022000376A
MX2022000376A MX2022000376A MX2022000376A MX2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A MX 2022000376 A MX2022000376 A MX 2022000376A
Authority
MX
Mexico
Prior art keywords
aminopyrimidines
alk inhibitors
formula
present disclosure
provides compounds
Prior art date
Application number
MX2022000376A
Other languages
English (en)
Inventor
Jianyong Chen
Shaomeng Wang
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2022000376A publication Critical patent/MX2022000376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación proporciona compuestos representados por la Fórmula I: (ver Fórmula) y sus sales, hidratos y solvatos aceptables desde el punto de vista farmacéutico, en donde R1a, R1b, R2a, R2b, R3, R4, R5, R6 y R7 son como se definen en la memoria descriptiva. La presente divulgación también proporciona compuestos de la Fórmula I para usarse en el tratamiento de una afección o trastorno que responde a la inhibición de ALK tal como el cáncer.
MX2022000376A 2016-08-29 2019-02-27 Aminopirimidinas como inhibidores de alk. MX2022000376A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29

Publications (1)

Publication Number Publication Date
MX2022000376A true MX2022000376A (es) 2022-02-10

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002393A MX2019002393A (es) 2016-08-29 2017-08-28 Aminopirimidinas como inhibidores de alk.
MX2022000376A MX2022000376A (es) 2016-08-29 2019-02-27 Aminopirimidinas como inhibidores de alk.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019002393A MX2019002393A (es) 2016-08-29 2017-08-28 Aminopirimidinas como inhibidores de alk.

Country Status (13)

Country Link
US (2) US10709705B2 (es)
EP (2) EP3504203B1 (es)
JP (2) JP7094566B2 (es)
KR (1) KR102530871B1 (es)
CN (2) CN109715620B (es)
AU (2) AU2017319135B2 (es)
BR (1) BR112019003897A2 (es)
CA (1) CA3033223A1 (es)
IL (1) IL264638B (es)
MX (2) MX2019002393A (es)
NZ (1) NZ751713A (es)
SG (2) SG11201901251SA (es)
WO (1) WO2018044767A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11478477B2 (en) 2018-07-31 2022-10-25 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
US20220117964A1 (en) * 2019-06-25 2022-04-21 Ascentage Pharma (Suzhu) Co., Ltd. Combination of fak inhibitor and btk inhibitor for treating a disease
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
WO2022222932A1 (en) * 2021-04-19 2022-10-27 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ES2424881T3 (es) 2003-08-15 2013-10-09 Novartis Ag 2,4-Di(fenilamino)-pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmunitario
CN100584832C (zh) * 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
RS52545B (en) * 2004-04-07 2013-04-30 Novartis Ag INHIBITORI PROTEIN APOPTOZE (IAP)
ES2524009T3 (es) 2006-12-08 2014-12-03 Irm Llc Compuestos y composiciones como inhibidores de la proteína quinasa
US8592432B2 (en) 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2627179A4 (en) 2010-10-14 2014-04-02 Ariad Pharma Inc METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS
EP2670401B1 (en) * 2011-02-02 2015-06-10 Novartis AG Methods of using alk inhibitors
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Also Published As

Publication number Publication date
KR20190039760A (ko) 2019-04-15
WO2018044767A3 (en) 2018-04-12
CA3033223A1 (en) 2018-03-08
IL264638B (en) 2021-08-31
AU2021203098A1 (en) 2021-06-10
NZ751713A (en) 2022-07-01
SG11201901251SA (en) 2019-03-28
AU2021203098B2 (en) 2023-05-25
JP7094566B2 (ja) 2022-07-04
WO2018044767A2 (en) 2018-03-08
US20190175595A1 (en) 2019-06-13
AU2017319135B2 (en) 2021-03-18
EP3504203B1 (en) 2022-09-28
MX2019002393A (es) 2019-07-08
EP3504203A2 (en) 2019-07-03
US20200330464A1 (en) 2020-10-22
SG10201914030UA (en) 2020-03-30
CN115043821A (zh) 2022-09-13
US11110090B2 (en) 2021-09-07
KR102530871B1 (ko) 2023-05-09
CN109715620A (zh) 2019-05-03
CN109715620B (zh) 2022-05-06
JP2022120151A (ja) 2022-08-17
BR112019003897A2 (pt) 2019-05-21
JP2019528307A (ja) 2019-10-10
US10709705B2 (en) 2020-07-14
EP4001273A2 (en) 2022-05-25
AU2017319135A1 (en) 2019-04-04
EP4001273A3 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
MX2022000376A (es) Aminopirimidinas como inhibidores de alk.
MX2018013433A (es) Piperidinas como inhibidores de menina.
MX2018012174A (es) Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2).
MX2019011412A (es) Piperidinas como inhibidores de menina covalentes.
SA519401020B1 (ar) مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2
MX2023006257A (es) Inhibidores de smyd.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
PH12016501388A1 (en) Heteroaryls and uses thereof
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
MX2016011992A (es) Derivados de piperidina-diona.
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
MX2017002986A (es) Compuestos de piperidina sustituidos.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2018004664A (es) Antagonistas de ep4.
CR20210265A (es) Derivados de aminopirimidina/pirazina como inhibidores de ctps1
PH12020551580A1 (en) Piperidine compounds as covalent menin inhibitor-0s
PH12021550374A1 (en) Small molecule menin inhibitors
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2017005423A (es) Inhibidores de histona desacetilasa y sus usos en terapia.